Rezolute, Inc. (NASDAQ: RZLT) is a Healthcare company (Biotechnology) with a market capitalization of $388M. The Maz Rating grades it against the other companies in its sector.
Rezolute, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $4.01, Rezolute, Inc. trades at 4.8x book value. It runs a gross margin of 0.0%, an operating margin of 0.0% and a net margin of 0.0%. It shows return on equity of -72.2%, return on invested capital of -94.7% and a free cash flow yield of -17.0%. On the balance sheet: a debt-to-equity ratio of 0.01 and a current ratio of 9.92. Over the past 52 weeks the share price ranged from $1.07 to $11.17, with a beta of 0.62.
Rezolute, Inc. does not currently pay a dividend.
14 Wall Street analyst ratings cover the stock: 14 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder, as well as for the treatment of hypoglycemia; and clinical trials of ersodetug for tumor hyperinsulinism. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Rezolute, Inc. (RZLT) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 20.5% / 30% · Interest income / Revenue 91800000.0% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 20.5% / 33% · Receivables / Mkt Cap (36m) 0.00% / 49% · Interest income / Revenue 91800000.0% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 20.5% / 33.33% · Receivables / Mkt Cap (24m) 0.00% / 33.33% · Interest income / Revenue 91800000.0% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 0.14% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 95.4% / 33.33% · Receivables / Avg Assets (4Q) 0.36% / 33.33% · Interest income / Revenue 91800000.0% / 5% | Fail |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 93.7% / 33.33% · (Cash+Recv) / Total Assets 93.7% / 33.33% · Interest income / Revenue 91800000.0% / 5% | Fail |
No. As of September 2026, Rezolute, Inc. (RZLT) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Rezolute, Inc. is over the AAOIFI limit on Interest income / Revenue.
About 91800000.0% of each dividend: Rezolute, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q1 2027). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.